Wilson disease revisited: is the gut a metabolically vulnerable target organ?

References

[1] Fang S,Azzi J,Debray D.Epidemiology and economic burden of Wilson disease in France: a nationwide population-based study.J Inherit Metab Dis2025;48:e12822 PMCID:PMC11670285

[2] Lu F,Xue X.Multifaceted role of copper homeostasis in gut health: from molecular mechanisms to therapeutic interventions.Cells2026;15:545 PMCID:PMC13024964

[3] Chen J,Shi H,Fan X.The molecular mechanisms of copper metabolism and its roles in human diseases.Pflugers Arch2020;472:1415-29

[4] European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson’s disease.J Hepatol2025;82:690-728

[5] Nilles C,Sobesky R.Diagnosis and outcomes of late-onset Wilson’s disease: a national registry-based study.Mov Disord2023;38:321-32

[6] Amin R,Fausak ED.Mitochondrial dysfunction in Wilson disease: a systematic review and meta-analysis across human and animal models.Front Mol Biosci2025;12:1712573 PMCID:PMC12753413

[7] Nagasaka H,Inui A.Relationship between oxidative stress and antioxidant systems in the liver of patients with Wilson disease: hepatic manifestation in Wilson disease as a consequence of augmented oxidative stress.Pediatr Res2006;60:472-7

[8] Polishchuk EV,Lichtmannegger J.Activation of autophagy, observed in liver tissues from patients with Wilson disease and from ATP7B-deficient animals, protects hepatocytes from copper-induced apoptosis.Gastroenterology2019;156:1173-89.e5

[9] Fontes A,Bierła JB.Copper impairs the intestinal barrier integrity in Wilson disease.Metabolism2024;158:155973

[10] Zhao L,Wang Y.Resistance role of Lactobacillus sp. and Lactococcus sp. to copper ions in healthy children’s intestinal microorganisms.J Hazard Mater2024;469:134059

[11] Wei T,Wang H.Wilson’s disease-associated gut dysbiosis: novel insights into microbial functional alterations, virulence changes, and resistance markers.Front Microbiol2025;16:1714276 PMCID:PMC12853645

[12] Albillos A,Rescigno M.The gut-liver axis in liver disease: pathophysiological basis for therapy.J Hepatol2020;72:558-77

[13] Gibbs K.Liver copper concentration in Wilson’s disease: effect of treatment with ‘anti-copper’ agents.J Gastroenterol Hepatol1990;5:420-4

[14] Lynderup EM,Kirk FT.Methanobactin rapidly facilitates biliary copper excretion in a Wilson disease rat model visualised by ⁶⁴Cu PET/MRI.Br J Pharmacol2026;183:268-79

[15] Engler J,Kim D.Rapid transcellular hepatic copper depletion by ARBM-101 rescues severe liver damage in Wilson disease rodents.Biomed Pharmacother2025;193:118867

[16] Einer C,Park E.ARBM101 (Methanobactin SB2) drains excess liver copper via biliary excretion in Wilson’s disease rats.Gastroenterology2023;165:187-200.e7

[17] Lichtmannegger J,Wimmer R.Methanobactin reverses acute liver failure in a rat model of Wilson disease.J Clin Invest2016;126:2721-35 PMCID:PMC4922707